ABSTRACT
OBJECTIVE: To evaluate occurrence of synchronous and metachronous malignant tumours, to find tumour types, age group, and relationship to treatment received. METHODS: Previously diagnosed 1st primary tumour cases experiencing a synchronous or metachronous tumour, seen at AOI from February 2003 to August 2009 (78 months) were included. The cases were analyzed for morphology/histology of 1st primary tumour, age and gender of patient, treatment received for first tumour, time interval between the 1st and 2nd primary tumour, morphology/histology of second tumour, and the treatment conferred for 2nd tumour. RESULTS: The 2nd synchronous and metachronous tumours were 46/4025 (1.14%), in 18 males and 28 females (M:F 1:1.6). The age range was 16-75 years (median 43 years). The follow up time was 24-150 months. The time to 2nd primary tumour was 2-132 months. The 1st primary tumours were breast, ovary, GIT and urinary bladder. The patients received surgery, radiotherapy, chemotherapy, and hormonal therapy alone or as multi-modality treatment for the 1st tumours. The frequent 2nd tumours were breast, ovary and Gastro Intestinal tumours. CONCLUSION: It is imperative that patients with a primary malignant tumour should be thoroughly, closely, and regularly followed. Genetic counseling, risk estimation, cancer screening and chemoprevention must be emphasized. Every subsequent occurring tumour should be biopsied. The effect of 1st tumour on the 2nd or vice versa are still not fully understood and need exploration. The 2nd primary tumour is usually more aggressive, treatment resistant, and metastasizes early requiring a more aggressive treatment strategy.
Subject(s)
Neoplasms, Multiple Primary/pathology , Neoplasms, Second Primary/pathology , Adolescent , Adult , Age Distribution , Aged , Biopsy , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Neoplasms, Multiple Primary/classification , Neoplasms, Multiple Primary/epidemiology , Neoplasms, Multiple Primary/therapy , Neoplasms, Second Primary/classification , Neoplasms, Second Primary/epidemiology , Neoplasms, Second Primary/therapy , Sex Distribution , Time Factors , Young AdultABSTRACT
BACKGROUND: The relation of nuclear morphometry measurements with clinicopathological features was evaluated along with prognosis in invasive female breast carcinoma in Libyan patients. Data was compared with corresponding results on Finnish, and Nigerian female breast cancer patients. PATIENTS AND METHODS: Histological samples from 131 patients of breast carcinoma were retrospectively studied by computerized nuclear morphometry. In each case, 50 nuclei were measured and the mean nuclear morphometric features were calculated and compared with different clinicopathological features, and patient's survival. RESULTS: There was statistically significant correlation between the mean nuclear area (MNA) and most clinicopathological features, with the strongest association observed for nuclear grade (p<0.0001). There was also correlation between nuclear area and tumor stage (p<0.04), tumor size (p<0.03) and lymph node (LN) status (p<0.001). A corresponding relationship was found between other size related features and clinical factors. The univariate analysis and survival analysis indicated that short survival time was associated with high nuclear morphometric values. MNA had negative correlation with length of survival (Pearson's test r=-0.29, p=0.019). Morphometric shape features did not show significant association with clinical features or survival. CONCLUSION: The results indicated that nuclear size features are reliable prognostic indicators in Libyan female breast carcinomas, as they were among Finnish and Nigerian females. The nuclear morphometric parameters can identify the aggressive tumor phenotype and provide significant prognostic information in predicting survival and tumors at risk of progression. The cut-off (71.0 mum(2)) of MNA might be applied as quantitative criterium for Libyan nuclear grading to separate patients into good and poor prognosis groups.
Subject(s)
Breast Neoplasms/pathology , Cell Nucleus/pathology , Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , PrognosisABSTRACT
BACKGROUND: Nuclear morphometry can be expected to improve the distinction between benign and malignant lesions. PATIENTS AND METHODS: Forty fine-needle aspiration biopsy (FNAB) samples fixed in 50% ethanol were collected at the African Oncology Institute, Sabratha, Libya, during the period 2004-2007. All diagnoses reported were confirmed histologically. There were 23 cases of infiltrating ductal carcinoma and 17 of benign breast disease. Two different assessment methods were applied: measurements made on cell groups, and those made on free cells. Apocrine metaplasia was excluded. Five different size parameters (include mean nuclear area, MNA) and 6 shape factors were measured. RESULTS: The size parameters showed significant differences between benign and malignant cases. The mean, median and 95% percentiles of nuclear area in both types of assessment were especially significant. The shape parameters were not significant. CONCLUSION: The study suggests that interactive computerized nuclear morphometry is an efficient and successful tool in distinguishing between cases of benign and malignant disease. Combination of our data with earlier free cell data gave the following diagnostic guidelines: Range of overlap in free cell samples: MNA 55 microm2 - 71 micro2. Cut-off values for diagnostic purposes: 100% detection of malignant cases: MNA > 54 microm2 (specificity 84%), 100% detection of benign cases: MNA < 72 microm2 (sensitivity 91%).
